-
EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
20 Apr 2024 12:31 GMT
… lung cancer: current treatment and future advances. Transl Lung Cancer Res … with small-cell lung cancer. Clin Lung Cancer. 2003;5(2 … . Non-small-cell lung cancers: a heterogeneous set of … loaded immunoliposomes functionalized with cetuximab: a novel strategy …
-
A Case of Punctate Psoriasis Following Treatment with Cetuximab in a Patient with Metastatic Gastric Adenocarcinoma
29 Apr 2024 08:25 GMT
Introduction
PD-1, a receptor known for its inhibitory effects, is predominantly expressed in T lymphocytes.1 It binds to specific ligands on the surface of tumor cells (PD-L1/PD-L2) and promotes the immune escape of tumor cells. Currently, a …
-
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 Apr 2024 16:30 GMT
… lung tumor diagnosis. This delay could result in the diagnosis of lung tumors … Reports: Lung Cancer Liquid Biopsy Market: Lung Cancer Liquid Biopsy … Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal …
-
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
02 Apr 2024 20:15 GMT
… , recurrent non-small cell lung cancer (“NSCLC”) who have previously … with non-small cell lung cancer (“NSCLC”) that cannot … patients with inoperable, recurrent lung cancer and patients amenable to … therapy, with or without cetuximab, for the treatment of …
-
Bristol Myers announces positive results from phase 1/ 2 KRYSTAL─1 study of Krazati in combo with cetuximab to treat patients with previously treated KRASG12C─mutated locally advanced or metastatic CRC
10 Apr 2024 10:19 GMT
… adagrasib) in combination with cetuximab for the treatment of … 94 patients, Krazati plus cetuximab demonstrated an objective response … metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined …
-
Krazati Plus Erbitux May Provide Clinical Benefit for Patients With Colorectal Cancer
09 Apr 2024 15:07 GMT
… factor receptor (EGFR) antibody cetuximab (Erbitux) showed clinical activity and … treat non-small cell lung cancer. “Treatment options are limited … treated with adagrasib plus cetuximab to those of … which compares adagrasib plus cetuximab to standard-of-care …
-
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
08 Apr 2024 15:42 GMT
… adagrasib) in combination with cetuximab for the treatment of … patients, KRAZATI plus cetuximab demonstrated an objective response … metastatic non-small cell lung cancer (NSCLC), as determined … metastatic non-small cell lung cancer (NSCLC), as determined …
-
Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
10 May 2024 16:36 GMT
… chimiothérapie en monothérapie ou le cétuximab. Merus estime qu’un essai … antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon … , in advanced non-small cell lung cancer (NSCLC) a été approuvée pour …
-
Merus gibt Finanzergebnisse für das erste Quartal 2024 bekannt und informiert über den aktuellen Geschäftsverlauf
10 May 2024 16:36 GMT
… mit einem einzigen Wirkstoff oder Cetuximab unterzogen. Darüber hinaus ist Merus … antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon … , in advanced non-small-cell lung cancer (NSCLC) (Wirksamkeit und Sicherheit von …
-
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
09 May 2024 20:50 GMT
… impressive results in small cell lung cancer. Shown on the right … , and non-small cell lung cancer. We believe that the … EGFR positive tumor types, including lung cancer, upper GI cancers, and … historical EGFR experience, say cetuximab, or is there anything …